NeurologyLive’s coverage of ACTRIMS Forum 2021 featured a number of insightful conversations with leading experts in multiple sclerosis care.
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, which ran virtually from February 25-27, featured a plethora of data presentations, including more than 300 posters and a wide variety of sessions, all focused on the central theme of the “The Spectrum of Multiple Sclerosis.”
As has been the case in years past, NeurologyLive provided coverage of these presentations straight from the conference floor, including the latest updates on therapies in clinical development, the assessment of clinical care strategies, the basic and translational science driving the understanding of MS pathogenesis, and the impact that the COVID-19 pandemic has had on patients and physicians.
Here, we highlight some of those interviews that the NeurologyLive team conducted during the conference, covering topics ranging from the use of disease-modifying therapies in early disease, the progressive phase of MS, and novel therapeutic strategies to the data collected in the COViMS registry and the real-world measurement of fatigue.
To view any of the interviews, click the corresponding image.
Multiple sclerosis (MS) can affect patients in a number of ways, but how the disease presents can change drastically over the course of a patient’s life. This, in turn, affects the way in which physicians must approach its treatment. Many disease-modifying therapies (DMTs) used to treat relapsing-remitting MS are, as Benjamin Segal, MD, puts it, “rendered ineffective in large part” once a patient transitions to progressive MS.
The difference between these states of disease and the inner workings of this transition process was the chosen topic of this year’s Kenneth P. Johnson Memorial Lecture at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2021, February 25-27, by Segal, who is the chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University. He additionally discussed how these differences relate to the current state of treatment for MS.
To find out more about the talk and why he chose to focus on this topic, NeurologyLive spoke with Segal in an interview. He offered his perspective on this transition from relapsing-remitting to progressive disease, and how this ultimately impacts treatment.